章雄文

章雄文

章雄文，男，博士，華東師範大學化學與分子工程學院教授。

基本介紹

  • 中文名：章雄文
  • 國籍：中國
  • 畢業院校：中國科學院上海藥物研究所
  • 學位/學歷：博士
  • 職業：教師
  • 專業方向：分子腫瘤藥理學
  • 職務：副主任
  • 任職院校：華東師範大學
研究方向,個人經歷,學術成果,

研究方向

從事分子腫瘤藥理學及分子靶向抗腫瘤新藥研發。
1. 抗腫瘤惡病質新藥研發
2. 腫瘤多藥耐藥逆轉劑新藥研發
3. 小分子激酶抑制劑抗腫瘤新藥研發
4. 雙/多靶點抗腫瘤新藥研發

個人經歷

1985年畢業於福建醫科大學醫療系獲學士學位，1991年畢業於福建醫科大學獲腫瘤藥理學專業碩士學位，1999年畢業於中科院上海藥物研究所獲分子腫瘤藥理學專業博士學位。1999-2002年在美國田納西大學和St. Jude兒童研究醫院從事博士後研究工作。2002年加入中科院上海藥物研究所國家新藥重點研究室腫瘤藥理組研究員。2006年加入亞盛醫藥研發有限公司任生物部總監。2007年加入羅氏研發中心（中國），先後任物篩選技術部主任、分子腫瘤部主任、體內藥理學部主任等職。2013年加入華東師範大學。國家藥品監督管理局（SFDA）藥品審評中心審評專家、中國藥理學會腫瘤藥理與化療專業委員會委員。在高質量雜誌上發表研究文章94篇，綜述14篇，9部專著部分章節的編撰，合作申請32項專利（17項授權）。先後主持多項國家科技部863和973課題及國家自然科學基金項目。參與發明一個1.1類新藥進入臨床，領導完成數個抗腫瘤新藥臨床前研發的完整過程，並領導參與新藥臨床I/IIa期實驗。在高質量雜誌上發表研究文章94篇，綜述14篇，申請專利32項（17項授權）。先後主持多項國家科技部863和973課題及國家自然科學基金項目。參與發明一個1.1類新藥進入臨床，領導完成數個抗腫瘤新藥臨床前研發的完整過程，並領導參與新藥臨床I/IIa期實驗。

學術成果

在高質量雜誌上發表研究文章94篇，綜述14篇。
代表性論文（Selected Research Publications）：
1. Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis 1 of IL-6 and tumor derived extracellular vesicles. J Cachexia Sarcopenia Muscle 2022; in press. (IF 12.91)
2. miR-126-5p affects the chemosensitivity of colorectal cancer cells 1 by targeting SPRED1, ERK1/2 pathway and apoptosis. Genes & Diseases 2022; Online. (IF 7.103)
3. The critical role of STAT3 in biogenesis of tumor-derived exosomes with potency of inducing cancer cachexia in vitro and in vivo. Oncogene 2022 Feb; 41(7):1050-1062. (IF 9.867)
4. Exosomes derived from colon cancer containing GDF15 promote muscle atrophy via Bcl-2/caspase-3 pathway. Cell Death Discovery. 2022 Apr; 8:162. (IF 5.24)
5. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway. Phytomedicine 2021 Nov; 95:153858. (IF 5.34)
6. Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome. J Cachexia Sarcopenia Muscle 2021; 12:1553-1569. (IF 12.91)
7. miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs. Cancers. 2021 July; 13: 3323. (IF 6.639)
8. Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle 2021 Jun;12(3):779-795. (IF 12.91)
9. Cancer-Derived Exosomes miRNAs Induce Skeletal Muscle Wasting by Bcl-2Mediated Apoptosis in Colon Cancer Cachexia. Mol Ther Nucleic Acids 2021 June; 24: 923-938. (IF 8.886)
3. Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res 2021 Apr; 11(4):1428-1445. (IF 6.166)
10. Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis. Mol Ther Nucleic Acids 2020 Jun 1; 21:229-241. (IF 8.886)
11. Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I. Acta Pharmacol Sin. 2020; 41(2):237-248. (IF 6.15)
12. NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3. Am J Cancer Res 2019; 9(11):2364-2378. (IF 6.166)
13. L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo. Front Pharmacol 2019; 10:89. (IF 5.81)
14. SiBaoChongCao exhibited anti-fatigue activities and ameliorated cancer cachexia in mice. RSC Adv. 2019 Jun; 9: 17440-56. (IF 3.361)
15. Design and synthesis of aryloxypropanolamine as β3-adrenergic receptor antagonist in cancer and lipolysis. Eur J Med Chem 2018; 150:757-770. (IF 6.514)
16. ES2 enhances the efficacy of chemotherapeutic agents in ABCB1-overexpressing cancer cells in vitro and in vivo. Pharmacol Res 2018; 129:388-399. (7.658)
17. Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors. Bioorg Med Chem. 2018 Jul 23; 26(12):3308-3320. (IF 3.641)
18. Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α. Acta Pharmacol Sin 2018；39(3):415-424. (IF 6.15)
19. Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis. Front Pharmacol 2017; 8:915. (IF 5.81)
20. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as noveland potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem 2017;126:1083-106. (IF 6.514)
21. Characterization of a near-infrared fluorescent dcpo-tagged glucose analogue for cancer cell imaging. J Photoch Photobio B 2017;166:264-71. (IF 6.252)
22. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. J Exp Clin Cancer Res 2016; 35(1):183-97. (IF 11.161)
23. Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle 2016; 15(7):895-907. (IF 4.534)
24. Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with a Novel Multifuctional Linker. Bioconjugate Chemistry 2016; 27(5):1267-75. (IF 4.774)
25. NIR fluorescent DCPO glucose analogues and their application in cancer cell imaging. RSC Adv 2016; 6(85): 81894-901. (IF 3.361)

相關詞條

熱門詞條

聯絡我們